These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29143971)

  • 21. The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry--mapping biotechnology's success.
    Evens RP; Kaitin KI
    Clin Pharmacol Ther; 2014 May; 95(5):528-32. PubMed ID: 24448474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.
    Litten RZ; Ryan M; Falk D; Fertig J
    Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges of biomarkers in drug discovery and development.
    Goodsaid F
    Expert Opin Drug Discov; 2012 Jun; 7(6):457-61. PubMed ID: 22471322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applying technologies towards safe and effective medicines.
    Roses AD
    Biotechniques; 2005 Oct; 39(4):563-4. PubMed ID: 16235568
    [No Abstract]   [Full Text] [Related]  

  • 25. New paradigm for drug developments--from emerging market statistical perspective.
    Quan H; Chen X; Zhang J; Zhao PL
    Contemp Clin Trials; 2013 Nov; 36(2):697-703. PubMed ID: 23810938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The biotechnology sector's craving for commercial expertise is fuelling a cultural exchange with drug industry.
    Smaglik P; Frantz S
    Nature; 2003 Apr; 422(6931):542-3. PubMed ID: 12673255
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety biomarker applications in drug development.
    Schomaker S; Ramaiah S; Khan N; Burkhardt J
    J Toxicol Sci; 2019; 44(4):225-235. PubMed ID: 30944276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growing pains in AIDS drug development.
    Herrera S
    Nat Biotechnol; 2004 Oct; 22(10):1194. PubMed ID: 15470440
    [No Abstract]   [Full Text] [Related]  

  • 29. How pharmaceutical industry funding affects trial outcomes: causal structures and responses.
    Sismondo S
    Soc Sci Med; 2008 May; 66(9):1909-14. PubMed ID: 18299169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How development and manufacturing will need to be structured--heads of development/manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Nepveux K; Sherlock JP; Futran M; Thien M; Krumme M
    J Pharm Sci; 2015 Mar; 104(3):850-64. PubMed ID: 25630721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Achieving continuous manufacturing for final dosage formation: challenges and how to meet them. May 20-21, 2014 Continuous Manufacturing Symposium.
    Byrn S; Futran M; Thomas H; Jayjock E; Maron N; Meyer RF; Myerson AS; Thien MP; Trout BL
    J Pharm Sci; 2015 Mar; 104(3):792-802. PubMed ID: 25501530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roadmap for implementation of quality by design (QbD) for biotechnology products.
    Rathore AS
    Trends Biotechnol; 2009 Sep; 27(9):546-53. PubMed ID: 19647883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan.
    Ohtsu Y; Matsumaru T; Katashima M; Kakehi M; Kakuo H; Suzuki T; Mabuchi M; Nakamura R; Nakamura T; Katori N; Tanaka S; Saito Y
    Bioanalysis; 2019 Jan; 11(2):55-60. PubMed ID: 30475072
    [No Abstract]   [Full Text] [Related]  

  • 34. Using health outcomes data to inform decision-making: a pharmaceutical industry perspective.
    Keech M
    Pharmacoeconomics; 2001; 19 Suppl 2():27-31. PubMed ID: 11700786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The rise of micropharma.
    Barden CJ; Weaver DF
    Drug Discov Today; 2010 Feb; 15(3-4):84-7. PubMed ID: 19837185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melding regulatory, pharmaceutical industry, and U.S. payer perspectives on improving approaches to heterogeneity of treatment effect in research and practice.
    Willke RJ; Crown W; Del Aguila M; Cziraky MJ; Khan ZM; Migliori R
    Value Health; 2013; 16(6 Suppl):S10-5. PubMed ID: 24034306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Back on target.
    Webb S
    Nat Biotechnol; 2013 Mar; 31(3):191-3. PubMed ID: 23471062
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimizing the use of CROs by academia and small companies.
    Lane RF; Friedman LG; Keith C; Braithwaite SP; Frearson JA; Lowe DA; Longo FM; Refolo LM; Watterson DM; Tsaioun K; Shineman DW; Fillit HM
    Nat Rev Drug Discov; 2013 Jul; 12(7):487-8. PubMed ID: 23812255
    [No Abstract]   [Full Text] [Related]  

  • 39. All systems go?
    Watson C
    Drug Discov Today; 2004 Dec; 9(24):1040-2. PubMed ID: 15582791
    [No Abstract]   [Full Text] [Related]  

  • 40. The role of clinical imaging in oncological drug development.
    Murphy PS; McCarthy TJ; Dzik-Jurasz AS
    Br J Radiol; 2008 Sep; 81(969):685-92. PubMed ID: 18541632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.